Sequent Scientific Financials
| SEQUENT Stock | 199.27 1.09 0.55% |
Operating Margin 0.0679 | PE Ratio 294.697 | Profit Margin 0.0039 | Return On Equity (0.04) |
Sequent | Select Account or Indicator |
Understanding current and past Sequent Scientific Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Sequent Scientific's financial statements are interrelated, with each one affecting the others. For example, an increase in Sequent Scientific's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Sequent Scientific's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sequent Scientific Limited. Check Sequent Scientific's Beneish M Score to see the likelihood of Sequent Scientific's management manipulating its earnings.
Sequent Scientific Stock Summary
Sequent Scientific competes with Biofil Chemicals, PB Fintech, JGCHEMICALS, Mtar Technologies, and Selan Exploration. Sequent Scientific is entity of India. It is traded as Stock on NSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE807F01027 |
| Business Address | Dosti Pinnacle, Mumbai, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.sequent.in |
| Phone | 91 22 4111 4777 |
You should never invest in Sequent Scientific without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Sequent Stock, because this is throwing your money away. Analyzing the key information contained in Sequent Scientific's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Sequent Scientific Key Financial Ratios
Sequent Scientific's financial ratios allow both analysts and investors to convert raw data from Sequent Scientific's financial statements into concise, actionable information that can be used to evaluate the performance of Sequent Scientific over time and compare it to other companies across industries.| Revenue | 13.7 B | ||||
| Gross Profit | 5.63 B | ||||
| EBITDA | 549.8 M | ||||
| Net Income | (358.69 M) | ||||
| Total Asset | 15.4 B |
Sequent Scientific Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 15.2B | 13.9B | 14.4B | 15.3B | 15.4B | 10.6B | |
| Other Current Liab | 474.9M | 734.6M | 418.9M | 134.1M | 393.8M | 610.9M | |
| Net Debt | 3.2B | 2.2B | 3.1B | 4.0B | 4.2B | 2.8B | |
| Cash | 681.0M | 537.4M | 575.0M | 415.7M | 648.1M | 354.1M | |
| Net Receivables | 3.2B | 3.5B | 3.3B | 3.4B | 3.4B | 2.0B | |
| Inventory | 2.2B | 2.6B | 3.5B | 3.5B | 3.5B | 3.6B | |
| Other Current Assets | 576.8M | 436.9M | 470.3M | 612.2M | 735.7M | 616.3M | |
| Total Liab | 7.3B | 6.2B | 7.0B | 7.8B | 8.3B | 5.7B | |
| Total Current Assets | 7.0B | 7.1B | 7.9B | 7.9B | 8.2B | 4.7B | |
| Short Term Debt | 2.0B | 1.4B | 2.0B | 2.6B | 3.2B | 2.0B | |
| Good Will | 2.4B | 1.7B | 1.9B | 2.4B | 2.3B | 1.5B | |
| Accounts Payable | 2.2B | 2.3B | 2.6B | 2.4B | 2.6B | 1.9B | |
| Intangible Assets | 517.0M | 443.9M | 559.5M | 684.2M | 617.2M | 535.8M | |
| Retained Earnings | (791.2M) | 599.7M | 888.9M | 996.9M | 1.2B | 1.3B | |
| Other Liab | 543.4M | 326.2M | 162.4M | 246.5M | 221.9M | 378.6M | |
| Net Tangible Assets | 4.5B | 5.1B | 4.5B | 3.9B | 4.5B | 4.5B | |
| Other Assets | 372.3M | 355.9M | 514.1M | 502.9M | (1.0) | (0.95) | |
| Long Term Debt | 1.5B | 937.1M | 1.2B | 1.8B | 1.4B | 1.3B | |
| Short Long Term Debt | 1.8B | 1.0B | 1.9B | 2.2B | 3.1B | 2.1B | |
| Long Term Debt Total | 2.0B | 1.4B | 1.2B | 2.2B | 2.0B | 1.3B | |
| Capital Surpluse | 8.6B | 8.7B | 8.7B | 9.0B | 8.1B | 7.2B |
Sequent Scientific Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 322.2M | 192.5M | 135.1M | 355.2M | 480.9M | 281.8M | |
| Total Revenue | 11.6B | 13.5B | 14.1B | 14.2B | 13.7B | 7.7B | |
| Gross Profit | 5.2B | 6.2B | 5.7B | 5.9B | 5.6B | 3.3B | |
| Operating Income | 1.3B | 1.7B | 579.6M | (153.5M) | 76.9M | 73.1M | |
| Ebit | 1.3B | 1.6B | 691.6M | (1.0B) | (65.6M) | (62.3M) | |
| Ebitda | 1.8B | 2.1B | 1.2B | (464.5M) | 549.8M | 628.6M | |
| Cost Of Revenue | 6.4B | 7.4B | 8.4B | 8.3B | 8.1B | 4.4B | |
| Income Before Tax | 940.8M | 1.4B | 533.9M | (1.4B) | (546.5M) | (519.1M) | |
| Net Income | 699.1M | 954.4M | 409.6M | (1.2B) | (358.7M) | (340.8M) | |
| Income Tax Expense | 120.3M | 321.8M | 83.3M | (156.8M) | (250.3M) | (237.8M) | |
| Minority Interest | 447.4M | 486.7M | (38.1M) | 8.2M | (62.6M) | (59.4M) | |
| Tax Provision | 120.3M | 321.8M | 83.3M | (156.8M) | (250.3M) | (237.8M) | |
| Interest Income | 306.5M | 243.8M | 157.7M | 513.1M | 590.1M | 337.2M | |
| Net Interest Income | (342.1M) | (243.8M) | (157.7M) | (355.2M) | (480.9M) | (504.9M) |
Sequent Scientific Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (193.1M) | (456.2M) | (1.1B) | 50.8M | 2.9M | 3.0M | |
| Change In Cash | 3.1M | (143.5M) | 37.5M | (159.2M) | 232.4M | 244.0M | |
| Free Cash Flow | 746.1M | 619.2M | (18.7M) | (693.7M) | (2.1M) | (2.2M) | |
| Depreciation | 506.2M | 506.0M | 510.9M | 556.9M | 615.4M | 398.2M | |
| Other Non Cash Items | 342.1M | 222.5M | 151.4M | 1.2B | 283.3M | 301.1M | |
| Capital Expenditures | 407.2M | 528.3M | 324.6M | 861.8M | 308.1M | 529.1M | |
| Net Income | 940.8M | 1.5B | 533.9M | (1.4B) | (358.7M) | (340.8M) | |
| End Period Cash Flow | 681.0M | 537.4M | 575.0M | 415.7M | 648.1M | 354.5M | |
| Investments | (389.7M) | 1.9B | 37.5M | (649.6M) | (59.2M) | (56.2M) | |
| Net Borrowings | 62.3M | (40.2M) | (1.3B) | 862.4M | 776.1M | 814.9M | |
| Change To Netincome | 531M | 396M | 275.6M | 1.3B | 1.5B | 1.6B |
Sequent Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sequent Scientific's current stock value. Our valuation model uses many indicators to compare Sequent Scientific value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sequent Scientific competition to find correlations between indicators driving Sequent Scientific's intrinsic value. More Info.Sequent Scientific Limited is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sequent Scientific's earnings, one of the primary drivers of an investment's value.Sequent Scientific Systematic Risk
Sequent Scientific's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sequent Scientific volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Sequent Scientific correlated with the market. If Beta is less than 0 Sequent Scientific generally moves in the opposite direction as compared to the market. If Sequent Scientific Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sequent Scientific is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sequent Scientific is generally in the same direction as the market. If Beta > 1 Sequent Scientific moves generally in the same direction as, but more than the movement of the benchmark.
Sequent Scientific Limited Total Assets Over Time
Sequent Scientific November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sequent Scientific help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sequent Scientific Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sequent Scientific Limited based on widely used predictive technical indicators. In general, we focus on analyzing Sequent Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sequent Scientific's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.07 | |||
| Information Ratio | 0.054 | |||
| Maximum Drawdown | 18.51 | |||
| Value At Risk | (4.63) | |||
| Potential Upside | 6.85 |
Additional Tools for Sequent Stock Analysis
When running Sequent Scientific's price analysis, check to measure Sequent Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sequent Scientific is operating at the current time. Most of Sequent Scientific's value examination focuses on studying past and present price action to predict the probability of Sequent Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sequent Scientific's price. Additionally, you may evaluate how the addition of Sequent Scientific to your portfolios can decrease your overall portfolio volatility.